Get the Stockscreener App
33.33
4.16%
1.33
After Hours:
33.51
0.18
+0.54%
Longboard Pharmaceuticals Inc stock is traded at $33.33, with a volume of 628.10K.
It is up +4.16% in the last 24 hours and down -7.62% over the past month.
Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. The company is working to improve a portfolio of centrally acting product candidates designed to be selective for specific G protein-coupled receptors (GPCRs). The company is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies.
See More
Previous Close:
$32.00
Open:
$32.08
24h Volume:
628.10K
Relative Volume:
0.92
Market Cap:
$1.30B
Revenue:
-
Net Income/Loss:
$-54.42M
P/E Ratio:
-13.06
EPS:
-2.5513
Net Cash Flow:
$-50.87M
1W Performance:
+1.28%
1M Performance:
-7.62%
6M Performance:
+54.31%
1Y Performance:
+499.46%
1-Day Range:
$31.38
$33.70
1-Week Range:
$30.70
$34.18
52-Week Range:
$3.60
$40.48
Longboard Pharmaceuticals Inc Stock (LBPH) Company Profile
Name
Longboard Pharmaceuticals Inc
Sector
Industry
Phone
619-592-9775
Address
4275 EXECUTIVE SQUARE, LA JOLLA
Longboard Pharmaceuticals Inc Stock (LBPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-27-23 | Initiated | B. Riley Securities | Buy |
| Apr-07-21 | Initiated | Evercore ISI | Outperform |
| Apr-06-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-06-21 | Initiated | Citigroup | Buy |
| Apr-06-21 | Initiated | Guggenheim | Buy |
View All
Longboard Pharmaceuticals Inc Stock (LBPH) Latest News
Longboard Pharmaceuticals' SWOT analysis: bexicaserin potential drives stock outlook By Investing.com - Investing.com UK
Marshall Wace LLP Trims Stock Position in Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) - MarketBeat
Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) Short Interest Update - MarketBeat
Lynx1 Capital Management LP Purchases Shares of 167,317 Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) - MarketBeat
Longboard Pharmaceuticals begins Phase III Dravet syndrome trial - Yahoo Finance
Longboard begins global Phase 3 trial for Dravet syndrome drug - Investing.com India
Longboard begins global Phase 3 trial for Dravet syndrome drug By Investing.com - Investing.com Canada
Longboard begins global Phase 3 trial for Dravet syndrome drug By Investing.com - Investing.com Australia
Longboard Pharmaceuticals Initiates Phase 3 DEEp SEA Study Evaluating Bexicaserin in Dravet Syndrome - StockTitan
Longboard Pharmaceuticals (NASDAQ:LBPH) Shares Up 3.5% - Defense World
Holdings of Longboard Pharmaceuticals Inc (LBPH) are aligned with the stars - SETE News
Longboard Pharmaceuticals (NASDAQ:LBPH) Shares Up 3.5% - MarketBeat
Man illegally sold recreationally caught rock lobster - Yanchep News Online
(LBPH) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) is Integral Health Asset Management LLC's 9th Largest Position - MarketBeat
Clarity Pharmaceuticals Issues New Employee Options - TipRanks
In the Green: Longboard Pharmaceuticals Inc (LBPH) Closes at 33.89, Up/Down 1.47 from Previous Day - The Dwinnex
Ally Bridge Group NY LLC Reduces Holdings in Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) - Defense World
Was Longboard Pharmaceuticals Inc (LBPH)’s session last reading good? - US Post News
Labyrinth Resources Director Bolsters Shareholding - TipRanks
Labyrinth Resources Limited completed the acquisition of Distilled Analytics Pty Ltd for AUD 10.2 million. - Marketscreener.com
Longboard Pharma gains on FDA designations for lead asset - MSN
American Century Companies Inc. Has $12.88 Million Stake in Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) - MarketBeat
Longboard Stock Soars on FDA Designations for Epilepsy Drug - MSN
Longboard Stock Soars on FDA Designations for Epilepsy Drug - Yahoo Finance UK
Stocks of Longboard Pharmaceuticals Inc (LBPH) are poised to climb above their peers - SETE News
Brokers Offer Predictions for Longboard Pharmaceuticals, Inc.'s Q3 2024 Earnings (NASDAQ:LBPH) - MarketBeat
Wedbush Comments on Longboard Pharmaceuticals, Inc.'s FY2027 Earnings (NASDAQ:LBPH) - MarketBeat
Longboard Stock Soars on FDA Designations for Epilepsy Drug - Yahoo Finance
Longboard Pharmaceuticals (NASDAQ:LBPH) Trading Up 8.4% Following Analyst Upgrade - MarketBeat
Longboard Pharma stock gains on FDA designations (NASDAQ:LBPH) - Seeking Alpha
Longboard Pharmaceuticals Shares Rise on FDA's Designations For Dravet Syndrome Treatment - MarketWatch
LBPH overperforms with a 6.27 increase in share price - US Post News
Longboard Pharmaceuticals Receives Rare Pediatric Disease Designation and Orphan Drug Designation for Bexicaserin (LP352) in Dravet Syndrome - Business Wire
Longboard Pharmaceuticals (NASDAQ:LBPH) Price Target Raised to $80.00 at HC Wainwright - Defense World
Longboard Pharmaceuticals (NASDAQ:LBPH) Shares Gap Up Following Analyst Upgrade - Defense World
Longboard Pharmaceuticals (NASDAQ:LBPH) Trading Down 5.4% After Insider Selling - Defense World
The Attractiveness of Investing In Longboard Pharmaceuticals Inc (LBPH) is Growing - Knox Daily
Longboard Pharmaceuticals Inc (LBPH) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
Longboard Pharma shares target raised, rating held post investor day By Investing.com - Investing.com India
Longboard Pharma shares target raised, rating held post investor day By Investing.com - Investing.com
Longboard Pharmaceuticals (NASDAQ:LBPH) Shares Gap Up on Analyst Upgrade - MarketBeat
Ratios Reveal: Breaking Down Longboard Pharmaceuticals Inc (LBPH)’s Financial Health - The Dwinnex
Camaraderie shines at Australian Longboard Titles - Echonetdaily
Baird maintains Outperform rating on Longboard Pharmaceuticals stock with steady price target - Investing.com
Longboard Pharmaceuticals (NASDAQ:LBPH) Given New $80.00 Price Target at HC Wainwright - MarketBeat
Guess which ASX biotech stock is surging 11% on big FDA news - The Motley Fool Australia
Baird maintains Outperform rating on Longboard Pharmaceuticals stock with steady price target - Investing.com India
Baird maintains Outperform rating on Longboard Pharmaceuticals stock with steady price target - Investing.com Australia
Longboard Pharmaceuticals (NASDAQ:LBPH) Price Target Increased to $44.00 by Analysts at Wedbush - MarketBeat
Baird maintains Outperform rating on Longboard Pharmaceuticals stock with steady price target - Investing.com Canada
Longboard Pharmaceuticals Inc Stock (LBPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):